In the gefitinib-resistant NSCLC subline PC9-R, which expresses the EGFR T790M (or T766M in alternative numbering system) mutation, sEVs are enriched with components of the Akt/mTOR signalling pathway, which confer to recipient cells not only protection against gefitinib, but also enhanced proliferation and invasion [155]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.